Literature DB >> 18031277

Stabilization of the active form(s) of human paraoxonase by human phosphate-binding protein.

D Rochu1, E Chabrière, F Renault, M Elias, C Cléry-Barraud, P Masson.   

Abstract

While there is a consensus that human PON1 (paraoxonase-1) has a protective role, its primary biological function remains unclear. A protective role against poisoning by organophosphates [OPs (organophosphorus compounds)] drove earlier works. Clinical interest has recently focused on a protective role of PON1 against vascular diseases. PON1 resides mainly on HDL (high-density lipoprotein) particles, and converging recent works show that both its activities and stability dramatically depend on this versatile and dynamic molecular environment. The discovery that HPBP (human phosphate-binding protein) has a firm tendency to associate with PON1 has steered new directions for characterizing PON1 functional state(s). Storage stability studies provided evidence that HPBP is involved in maintaining physiologically active PON1 conformation(s). Thermal stability studies showed that human PON1 is remarkably thermostable and that its association with HPBP strongly contributes to slowing down the denaturation rate. A hybrid PON1, displaying mutations that stabilized recombinant enzyme expressed in Escherichia coli, was shown to be more thermostable than natural human PON1. Predictably, its stability was unaffected by the presence of HPBP. Synergistic efforts on characterizing natural PON1 and rPON1 (recombinant PON1) provide information for the design of future stable mutants of PON1-based bioscavengers to be used as safe and effective countermeasures to challenge OPs. Maintaining a stable environment for such administrable human rPON1 should, at least, preserve the anti-atherogenic activity of the enzyme.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18031277     DOI: 10.1042/BST0351616

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  11 in total

Review 1.  For whom the bell tolls? DING proteins in health and disease.

Authors:  Anne Berna; François Bernier; Eric Chabrière; Mikael Elias; Ken Scott; Andrew Suh
Journal:  Cell Mol Life Sci       Date:  2009-03-17       Impact factor: 9.261

Review 2.  DING proteins: numerous functions, elusive genes, a potential for health.

Authors:  François Bernier
Journal:  Cell Mol Life Sci       Date:  2013-06-07       Impact factor: 9.261

3.  Human X-DING-CD4 mediates resistance to HIV-1 infection through novel paracrine-like signaling.

Authors:  Rakhee Sachdeva; Yuchang Li; Rasheda Y Shilpi; Malgorzata Simm
Journal:  FEBS J       Date:  2015-01-27       Impact factor: 5.542

4.  DING proteins from phylogenetically different species share high degrees of sequence and structure homology and block transcription of HIV-1 LTR promoter.

Authors:  Rakhee Sachdeva; Nune Darbinian; Kamel Khalili; Shohreh Amini; Daniel Gonzalez; Ahmed Djeghader; Eric Chabriére; Andrew Suh; Ken Scott; Malgorzata Simm
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

5.  The level of DING proteins is increased in HIV-infected patients: in vitro and in vivo studies.

Authors:  Ahmed Djeghader; Gerard Aragonès; Nune Darbinian; Mikael Elias; Daniel Gonzalez; Anabel García-Heredia; Raúl Beltrán-Debón; Rafal Kaminski; Guillaume Gotthard; Julien Hiblot; Anna Rull; Olivier Rohr; Christian Schwartz; Carlos Alonso-Villaverde; Jorge Joven; Jordi Camps; Eric Chabriere
Journal:  PLoS One       Date:  2012-03-09       Impact factor: 3.240

6.  Structural insights and ab initio sequencing within the DING proteins family.

Authors:  Mikael Elias; Dorothee Liebschner; Guillaume Gotthard; Eric Chabriere
Journal:  J Synchrotron Radiat       Date:  2010-11-05       Impact factor: 2.616

7.  Human-Phosphate-Binding-Protein inhibits HIV-1 gene transcription and replication.

Authors:  Thomas Cherrier; Mikael Elias; Alicia Jeudy; Guillaume Gotthard; Valentin Le Douce; Houda Hallay; Patrick Masson; Andrea Janossy; Ermanno Candolfi; Olivier Rohr; Eric Chabrière; Christian Schwartz
Journal:  Virol J       Date:  2011-07-15       Impact factor: 4.099

8.  Catalytic bioscavengers against toxic esters, an alternative approach for prophylaxis and treatments of poisonings.

Authors:  Patrick Masson; Daniel Rochu
Journal:  Acta Naturae       Date:  2009-04       Impact factor: 1.845

Review 9.  Human paraoxonase 1 as a pharmacologic agent: limitations and perspectives.

Authors:  Priyanka Bajaj; Rajan K Tripathy; Geetika Aggarwal; Abhay H Pande
Journal:  ScientificWorldJournal       Date:  2014-10-20

10.  Eukaryotic DING proteins are endogenous: an immunohistological study in mouse tissues.

Authors:  Jean-Marc Collombet; Mikael Elias; Guillaume Gotthard; Elise Four; Frédérique Renault; Aurélie Joffre; Dominique Baubichon; Daniel Rochu; Eric Chabrière
Journal:  PLoS One       Date:  2010-02-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.